Investigation of Asprosin a Novel Adipokine in Periodontitis

Ataturk University

Status: Completed

Conditions: Periodontitis; Diabetes Mellitus; Obesity

Treatments: Diagnostic Test: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Study type: Observational

Funder types: Other

Identifiers

NCT05449821

MIC2

Details and patient eligibility

About

Asprosin, a recently discovered glucogenic adipokine, is mainly synthesized by white adipose tissue and released during fasting. Appetite, glucose metabolism, insulin resistance, cell apoptosis, etc. asprosin is associated with diseases such as diabetes, obesity, polycystic ovary syndrome, and cardiovascular diseases. Periodontal tissue may act as a source of endocrine-like inflammatory mediators (such as TNF-α, IL-6 and IL-1) that are important in periodontal inflammation and can affect glucose and lipid metabolism. Production of TNF-α and IL-6 in adipose tissues strengthens the relationship between obesity, T2DM and periodontitis.we postulated that asprosin may be candidate for explaining the triangular relationship among obesity, T2DM, and periodontal disease.

Full description

Periodontal disease is a chronic, multifactorial, and infectious disease caused by bacteria. It is characterized by the formation of an inflammatory response in the supporting bone and connective tissue against microbial dental plaque, and the nature of the resulting inflammatory response determines the course of periodontal disease. Type 2 Diabetes Mellitus (T2DM), obesity, and periodontal disease are closely related, presenting a triad association. Obesity is the crucial cause of T2DM and periodontitis is the sixth complication of diabetes. Asprosin circulates in the blood at nanomolar levels and is taken to the liver, where it activates the G protein-cAMP-PKA pathway, causing rapid glucose release into the circulation. Insulin-resistant humans and mice have been reported to have pathologically elevated plasma asprosin levels. It will be investigated whether asprosin, which we know to be effective on glucose metabolism, is affected by the periodontal condition.

Enrollment: 65 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: -

• All individuals were generally healthy,
• non-smoking

Exclusion Criteria:

• Pregnant or breastfeeding women
• None had undergone periodontal therapy and/or antibiotic therapy in the past 6 months.
• None has a contagious disease such as HIV or AIDS

Trial design

65 participants in 2 patient groups

Periodontitis group

Description:

35 subjects had periodontitis. Periodontitis will be staged by including patients with a periodontal pocket (PD) measurement of 4 mm and above, accompanied by attachment loss and radiographic bone loss.

Treatment:

Diagnostic Test: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis

Healthy group

Description:

30 subjects had healthy periodontal tissue.Healthy controls included volunteers with clinically healthy gingiva on an intact periodontium who had BOP \< 10% and PD ≤ 3 mm, no sites with attachment loss, no radiographic sign of alveolar bone destruction, and no history of periodontitis.

Treatment:

Diagnostic Test: Serum and salivary samples will be collected. Asprosin levels will be determined by biochemical analysis